Why lilly Is Trending Today?

Eli Lilly and Company experienced a significant 54% increase in revenue during the third quarter of 2022, largely driven by the success of its weight loss drugs, Mounjaro and Zepbound. This impressive growth led the company to revise its 2025 forecast upwards. The pharmaceutical giant's stock price also surged by 7% following this news. The strong performance of these drugs, particularly Zepbound, which saw its sales nearly triple at lower prices, contributed to Eli Lilly blowing past analysts' expectations. In response to the high demand for Zepbound, Eli Lilly has partnered with Walmart to offer the first retail pickup option for discounted vials of the drug, marking a significant step in the direct-to-consumer pricing strategy.